ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CRBP Corbus Pharmaceuticals Holdings Inc

38.67
3.10 (8.72%)
Last Updated: 12:59:32
Delayed by 15 minutes

Period:

Draw Mode:

Volume 73,018
Bid Price 38.34
Ask Price 38.90
News -
Day High 39.73

Low
3.0334

52 Week Range

High
49.8699

Day Low 35.1636
Company Name Stock Ticker Symbol Market Type
Corbus Pharmaceuticals Holdings Inc CRBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
3.10 8.72% 38.67 12:59:32
Open Price Low Price High Price Close Price Prev Close
35.42 35.1636 39.73 35.57
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,674 73,018 $ 37.86 $ 2,764,701 - 3.0334 - 49.8699
Last Trade Time Type Quantity Stock Price Currency
12:59:31 15 $ 38.66 USD

Corbus Pharmaceuticals Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
409.23M 10.49M - 0 -42.35M -4.04 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Corbus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CRBP Message Board. Create One! See More Posts on CRBP Message Board See More Message Board Posts

Historical CRBP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week38.7039.7333.239836.34252,852-0.03-0.08%
1 Month28.2549.869926.818839.61402,78410.4236.88%
3 Months6.0549.86995.665429.24991,20532.62539.17%
6 Months6.3549.86993.033428.80468,52332.32508.98%
1 Year6.6949.86993.033426.87259,96131.98478.03%
3 Years57.83468.702.1121.861,382,468-19.16-33.14%
5 Years208.50322.502.1166.232,212,690-169.83-81.45%

Corbus Pharmaceuticals Description

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Your Recent History

Delayed Upgrade Clock